Last updated: May 3, 2026
What does EP4687899 cover, and how broad are its claims in Europe?
Scope in plain terms
EP4687899 is an EPO patent application that contains a drug-related claim set framed around a specific active ingredient and its use in therapeutic regimens. The patent document’s scope is best understood by mapping: (i) the claimed compound(s), (ii) the claimed pharmaceutical formulation(s), and (iii) the claimed medical use(s) (treatment method, population, disease stage, dosing schedule, or combination therapy).
The European patent landscape around EP4687899 is shaped by three layers of prior art:
- Compound-level prior art (same or closely related chemical structures; same active ingredient across different salt/solvate polymorphs)
- Formulation-level prior art (tablet, capsule, inhalation, controlled-release, excipient systems, particle size, coating)
- Use-level prior art (treatment indication, patient subgroup, dosing regimen, and combinations)
What “scope” usually means for enforcement
In Europe, practical enforceability of EP-family claims turns on whether the granted scope (once available) ties to:
- A product that falls within the compound or formulation claim language (direct infringement)
- A therapeutic use claim where infringement can be triggered by “making available for use” under Article 54/European practice around Swiss-type/EPC-style use categories
- Combination claims where either both components are present, or the claim language permits component substitution without leaving the literal wording
For EP4687899 specifically, the ability to enforce against generics hinges on whether any independent claim is written as:
- “Use of compound X for treating condition Y” (use-based protection; often harder to avoid via manufacturing changes)
- A formulation claim that is independent of indication (product-based; easier to map to manufacture/import)
- A dosing regimen claim (strong if regimen is tightly defined; weaker if regimen is generic and already disclosed)
Claim structure: what is likely independent vs. dependent, and where breadth comes from
Independent claims: the levers
EP drug filings typically have independent claim categories such as:
- Compound claims (Markush structure around core scaffold, substituent ranges, stereochemistry)
- Compositions (pharmaceutical composition comprising compound X plus defined excipients)
- Methods of treatment (use for treating disease Y, including dose and schedule)
- Combinations (compound X with a second agent A for treating Y)
Breadth is driven by:
- Whether substituent variables are open-ended (wider) or restricted (narrower)
- Whether “pharmaceutically acceptable” is used broadly (wider)
- Whether the claim defines strict regimen endpoints (narrower) or generic dosing ranges (wider)
- Whether the indication is disease-level vs. biomarker-subgroup-level (biomarker-level is typically narrower)
Dependent claims: refinement and “claim stacking”
Dependent claims usually narrow scope by:
- Specifying salt forms, solvates, polymorphs
- Specifying particle size, dissolution profile, or release kinetics
- Specifying patient subgroup (biomarker-positive, prior therapy status)
- Specifying exact dosing units (mg, mg/kg) and schedule
- Specifying second therapeutic agent(s) and sequence
A key landscape point for investors: dependent claims can create a “layer cake” that supports partial validity if broad independent claims face novelty/obviousness pressure.
Scope vs. prior art: where EP4687899 sits in the European patent landscape
Category map (what matters for freedom-to-operate)
For EP4687899, the practical landscape question is not “is the compound known,” but “what exact claim elements are novel vs. disclosed” across three axes:
-
Chemical identity
- Known core scaffold disclosures
- Known substituent patterns that overlap the EP4687899 definitions
- Known salts/solvates and polymorphs that match EP language
-
Therapeutic use
- Prior art describing the same indication for the same compound
- Prior art describing different indications (which can still be relevant for inventive step)
- Prior art biomarker or line-of-therapy stratifications
-
Regimen and combinations
- Prior art dosing schedules
- Prior art combination therapies that include the second agent specified in EP4687899
- Prior art that teaches sequence or concomitant dosing
How EPO novelty/inventive step analysis typically compresses breadth
At the EPO, claim scope is attacked by:
- Novelty if all elements are disclosed in one prior art reference
- Inventive step if the closest prior art plus a motivation to modify leads to the claimed subject matter
If EP4687899 has:
- A broad Markush: expect stronger novelty pressure on the scaffold and substituent ranges
- A narrow biomarker subgroup: expect weaker novelty risk but higher risk on inventive step if similar subgroup disclosures exist
- A dosing regimen: novelty can survive longer, but inventive step can still collapse if regimens are routine and disclosed with rationale
Landscape pressure points in Europe for drug EP filings
1) Same active ingredient, different claim wrappers
If EP4687899 covers an active ingredient already disclosed in earlier European families, the fight often shifts to:
- Salt/polymorph exclusivity
- Specific formulation tech (release, particle engineering)
- A specific indication or patient subgroup
2) Filing dates vs. earlier disclosures
Landscape impact depends on:
- Whether EP4687899 has an effective date (priority) that predates the key prior art disclosure
- Whether earlier patents disclose the same claim elements implicitly or explicitly
3) Multi-jurisdiction families and EPO claim alignment
When a drug patent family is filed globally, EPO prosecution often narrows claims. A common landscape pattern:
- US/WO claims are broader
- EPO claims become more specific after Art. 54/56 objections
- Pending or granted EP claims can coexist with later divisional continuations
This affects value because generic entry risk tracks granted claim scope, not initial filing breadth.
Enforcement readiness: what must be true for EP4687899 to block generics
To block generics in practice, at least one of the following must be in force at grant:
- A compound claim that reads on the generic active ingredient (or its defined chemical variants)
- A composition claim that maps directly to formulation manufacture
- A therapeutic use claim that generics cannot avoid through labeling-only strategies
If EP4687899 is still pending, business decisions should treat it as a “risk-managed claim set” rather than an assured barrier. In particular, if the application’s independent claims are narrow, it can still protect a niche use while leaving other commercialization routes open.
What would a freedom-to-operate assessment focus on around EP4687899?
A business-grade FTO map typically enumerates claim-impact zones:
- Active ingredient identity: does the wording cover the exact compound used in the generic candidate?
- Formulation elements: does the generic formulation use the same release profile/particle specs or fall outside?
- Indication and dosing: can the competitor market outside the claimed use or use a different regimen?
Where EP4687899 includes combination claims, FTO must also assess:
- Whether the competitor uses the exact second agent(s)
- Whether the claim requires concurrent dosing versus sequential administration
Key takeaways
- EP4687899’s scope is determined by the interaction of compound, formulation, and therapeutic use claim elements.
- Claim breadth in the EPO context typically depends on how open-ended the chemical and formulation definitions are, and how tight the indication and regimen restrictions are.
- The European patent landscape risk for EP4687899 centers on prior art that overlaps at any one of three layers: compound identity, formulation attributes, and use/regimen/combination details.
- For commercial blocking power, value depends on what independent claims look like at grant, not at filing, and whether at least one independent category is enforceable without requiring multiple dependent-claim stacking.
FAQs
1) Does EP4687899 likely rely on compound coverage or use coverage?
Most drug EP filings rely on a mix, but enforcement strength usually comes from whichever independent claims remain after EPO prosecution. Use-based claims are strongest when tightly tied to a defined indication or regimen.
2) What claim features most affect breadth at the EPO?
Open chemical definitions (Markush ranges), broad “pharmaceutically acceptable” language, and generic dosing schedules expand scope. Biomarker-defined subgroups, strict dose schedules, and narrowly defined salts/polymorphs narrow scope.
3) How does the EPO treat prior art on different indications?
Different indication prior art can still be relevant for inventive step, especially if the motivation to use the same compound for the new indication is supported by the prior art disclosures.
4) Can competitors avoid EP drug protection by changing formulation?
If EP4687899 includes composition claims tied to specific formulation attributes (release kinetics, particle size, excipients), then formulation changes can create design-around opportunities. If protection is mainly through therapeutic use claims, design-around is harder.
5) What matters for generics: granted claims or pending claims?
Granted claims matter for enforceability. Pending claims can influence licensing and entry planning but should not be treated as a guaranteed barrier.
References (APA)
[1] European Patent Office. (n.d.). European Patent Register: EP4687899. EPO.
[2] European Patent Office. (2020). European Patent Convention (EPC): Articles 54 and 56. EPO.
[3] European Patent Office. (2020). Guidelines for Examination in the EPO. EPO.
